Articles tagged with Melanoma
Researchers at Sanford-Burnham Medical Research Institute have unraveled the relationship between MITF and ATF2, a transcription factor involved in melanoma development. The study reveals that the ratio of ATF2 to MITF in melanoma cells can predict survival in melanoma patients.
Researchers at Mount Sinai School of Medicine have discovered a protein that suppresses the progression of malignant melanoma by regulating an oncogene called CDK8. The study found that when macroH2A is present in early-stage melanoma, it slows down the disease's growth and metastasis.
A study of US adults found that women are more likely to use indoor tanning facilities than men, while few tanners mention reducing skin cancer risk. The prevalence of indoor tanning among US adults is relatively low, with 18.1% of women and 6.3% of men reporting use in the past year.
Researchers at Indiana University School of Medicine introduce a potent anti-tumor gene into mice with metastatic melanoma, resulting in complete remission and permanent immune reconfiguration. The gene therapy uses modified lentivirus to deliver a T cell receptor gene that recognizes specific melanoma proteins.
Researchers have identified a novel oncogene GNA11 associated with uveal melanoma in over 40% of tumor samples. This discovery offers new targets and treatments for the disease, which affects about 1,500 people in the US each year.
A survey of patients undergoing skin cancer screening reveals that women are more likely to seek screening due to a skin lesion, family history, or sun exposure concerns. In contrast, men over 50 tend to only seek screenings after a previous skin cancer diagnosis.
A new melanoma treatment has shown a robust activity in shrinking brain metastases in patients with advanced disease. The drug, GSK2118436, targets the BRAF protein mutation common in human melanomas and has been found to control and reduce brain tumor size in nearly all patients.
A new targeted therapy called PLX4032 has been linked to an 80% response rate in treating advanced melanoma. The treatment, which targets the BRAF protein, has shown significant tumor shrinkage and improved quality of life for some patients.
A phase 1 clinical trial showed that PLX4032 significantly shrinks tumors in over 80% of patients with metastatic melanoma and the mutated BRAF gene. The drug has also improved quality of life by reducing symptoms such as pain and fatigue within a week.
A study comparing melanoma incidence in Florida to national estimates found that Hispanic men had a 20% higher rate, while female non-Hispanic black individuals had a 60% higher rate. In contrast, female Hispanic patients were 30% less likely to develop the disease.
A new study from Queen's University has found that the growth of malignant melanoma can be slowed when MicroRNA 193b is added. Increased levels of miR-193b led to lower levels of cyclin D1 and decreased melanoma cell growth.
RG7204, a BRAF inhibitor, has shown significant preclinical activity against melanoma by inhibiting proliferation of tumor cell lines and inducing partial or complete tumor regression. The compound also improved survival rates without associated toxicity in preclinical models.
Identification of IKKβ as a crucial signaling molecule in melanoma development may lead to new targeted therapies. The study suggests that treating patients with specific genetic profiles could enhance treatment efficacy.
A preclinical study suggests combining targeted therapy against the BRAF/MAPK pathway with immunotherapy may improve durability of responses in treating melanoma. Researchers found that inhibiting the MAPK pathway resulted in increased antigen expression, leading to improved recognition by T-cells.
Researchers found that adding sorafenib to chemotherapy regimens does not improve patient survival in advanced melanoma patients. The study, sponsored by ECOG, enrolled 823 patients and did not confirm promising results from previous phase II studies.
A new chemotherapy delivery method has shown promising results in treating advanced melanoma patients with liver metastasis. The phase III trial demonstrated a significant increase in progression-free survival rates and controlled tumors in the liver.
A nearly 2,300-person study by the University of Minnesota definitively links indoor tanning to increased risk of melanoma, with frequent users facing a 74% higher likelihood. The study found that risk is associated more with how much a person tans and not the age or device type.
Researchers from the NYU Cancer Institute will present studies on improved ways to diagnose melanoma in lymphatic vessels and investigate genetic differences between melanoma subtypes. Laura Hogan, a pediatric hematology and oncology fellow, is also honored for her outstanding work in pediatric oncology research.
Researchers found warning young women about the effects on their appearance caused a 35% drop in indoor tanning visits. The study suggested that focusing on appearance is more effective than just skin cancer warnings, and offering alternative options can help individuals change their behavior.
A fish model experiment reverses an earlier finding linking early life UVA exposure to melanoma development. The study finds that UVB exposure is a significant cause of melanoma in the model, contradicting previous research. This new evidence sheds light on the role of UVA and UVB in skin cancer.
Researchers found that late-stage melanoma treatment for people over 65 years old results in substantial economic burdens, with average monthly charges ranging from $902 to $3,933. Early detection and treatment can significantly reduce these costs by up to 40-65%.
Two studies reveal a significant increase in non-melanoma skin cancers in the US, with over 13 million Americans affected by 2007. The disease is associated with substantial illness and cost, and continues to be a major public health concern.
Researchers at Johns Hopkins University have developed a noninvasive infrared scanning system to help doctors determine whether pigmented skin growths are benign moles or deadly melanoma. The system works by looking for tiny temperature differences between healthy tissue and growing tumors.
A study published in Genome Research has identified 11 novel gene fusions and 12 cases of chimeric transcripts in melanoma tumors. These genomic alterations, including rearrangements of genes and altered protein function, may play a role in the disease.
A study found that melanoma incidence rates increased 2.4 percent per year among white non-Hispanic individuals, while Hispanic and black patients had more advanced melanoma at diagnosis, suggesting the need for targeted education and screening campaigns to address disparities in melanoma outcomes
Researchers at NYU Langone Medical Center have identified hundreds of genes linked to patient survival in advanced melanoma. The study used DNA-microarray technology to find genes involved in the immune response and gene proliferation, providing a new framework for personalized medicine.
A recent study found that radiation therapy significantly improves regional recurrence control in melanoma patients who underwent lymphadenectomy. The treatment reduced the risk of cancer returning to the lymph nodes by 12 percentage points compared to observation.
A team of University of Alberta researchers successfully synthesized a natural substance called Palmerolide A, which shows exceptional potential to specifically treat melanoma. The potency of palmerolide is exceptional and may prove to be more effective with less toxicity than current chemotherapy approaches.
A survey of resident physicians found that many are not trained in skin cancer examinations, with only a small percentage reporting skill levels in performing the procedure. The study highlights the need for comprehensive training programs to teach this essential skill.
Researchers found that tanned very-light-skinned children with no red hair develop more nevi than untanned counterparts. The study suggests tanning avoidance may reduce melanoma risk in this population.
Researchers have identified a new group of genetic mutations involved in melanoma, with ERBB4 being the most frequently mutated PTK gene. The discovery could lead to specific therapies for melanoma patients with ERBB4 mutations.
A recent randomized trial found no association between antioxidant supplementation and melanoma risk in women. Long-term use of beta carotene and selenium also showed no link to melanoma risk. The study included over 69,000 participants and provided new insights into the potential benefits and harms of antioxidant supplements.
A study found that dermatologists detected 56.3% of all melanomas and 60% of in situ melanomas, compared to 54.5% for patient-detected cases. Dermatologist detection was also associated with thinner melanomas, with median depths of 0.33mm for physician-detected cases versus 0.55mm for patient-detected cases.
A phase II trial found that budesonide did not reduce the rate of diarrhea in patients with stage III or IV melanoma taking ipilimumab. The study showed a median overall survival of 17.7 months among those treated with budesonide, similar to those receiving placebo.
Researchers are testing a tumor-specific protein called recombinant human melanoma antigen A3 (MAGE-A3) to track down and kill cancer cells in patients with recurring melanoma. The study aims to generate a search-and-destroy program targeting deadly melanoma cells through the immune system.
Researchers identified eight risk factors for the transformation of choroidal nevi, benign flat pigmented growths inside the eye, into melanoma. These factors include tumor thickness greater than 2mm, fluid beneath the retina, and orange pigment.
Primary care physicians will receive web-based training on melanoma screening through a new program developed with a team of researchers. The goal is to improve detection and reduce mortality rates from melanoma.
A TGen-led research team has been awarded a $1 million grant by the Melanoma Research Alliance to identify novel melanoma risk genes. The team, led by Dr. Jeffrey Trent, aims to characterize genes influencing melanoma risk and develop targeted screening or prevention efforts.
Scientists at QIMR have discovered two genes that significantly increase the risk of developing melanoma in people with multiple moles. This groundbreaking research will help develop new screening techniques and potentially lead to new therapies for this deadly skin cancer.
A study published in Nature Genetics found that genetic patterns on chromosomes 9 and 22 are associated with an increased risk of melanoma. People carrying these genes are around eight times more likely to develop the disease than those with no variants.
A new region of the genome associated with an increased risk of melanoma has been identified by researchers at Leeds University and IDIBAPS, funded by the European Commission. The study found a link between this region and skin pigmentation, as well as two previously identified regions linked to melanoma risk.
Researchers at the University of Pittsburgh Cancer Institute have identified eight genes that can predict a patient's response to melanoma treatment. The study, presented at the ASCO annual meeting, used Neural Network Analysis to survey over 25,000 genes and regulators in tumor tissues from 21 patients with metastatic melanoma.
Researchers at NYU Langone Medical Center report early promise in animal studies for a novel antiparasitic drug as a potential treatment for metastatic melanoma. Additionally, the study found associations between specific microRNAs and patient survival in metastatic melanoma and early-stage lung cancer.
A team of scientists has identified the molecular structure of hemocyanin, a protein complex involved in skin and hair coloring. The study reveals how hemocyanin is activated, leading to an understanding of both albinism and melanoma.
Researchers found that imiquimod cream, used with surgery, can treat lentigo maligna melanoma, a type of skin cancer. This approach may reduce the area needing surgery, manage the cancer, and minimize its recurrence. The study suggests that imiquimod could be an effective treatment option for some patients.
A BUSM study found that using photographs of UV exposure motivates preteens to adopt better sun protection habits, resulting in a 36% lower reported sunburn rate compared to a control group. The UV photographs also helped identify high-risk students who benefited from the intervention.
Research identifies genetic variants in MC1R as associated with increased melanoma risk in people with dark hair. The study found that these variants were more common in those who did not typically burn easily from the sun, suggesting a complex relationship between genetics and melanoma risk.
A survey found that thinner melanomas are more likely to be detected by physicians, while thicker tumors are often self-detected. Physician skin examination and improved public awareness are key targets for new interventions to promote earlier detection.
A UCSF research team has developed a technique to diagnose melanoma by measuring differences in levels of genetic markers, with a success rate higher than 90 percent. The new strategy distinguished between benign and malignant skin lesions, shedding light on difficult-to-diagnose cases.
Researchers at the NIH/National Human Genome Research Institute have discovered a new tumor suppressor gene, MMP-8, that helps prevent melanoma growth. The finding may lead to more individualized cancer treatment strategies and improved outcomes for patients.
A new study found that a genetic variation increases melanoma risk in pre-menopausal women, with over 40% of those under 50 carrying the mutation. This discovery could lead to more effective surveillance and prevention strategies for this deadly skin cancer.
Researchers found that overexpressing SOX9 restores retinoic acid sensitivity in melanomas and stops tumor growth. A combined therapeutic strategy may provide new hope for treating RA-resistant cancers like melanoma.
A new study published in Ophthalmology highlights the association between skin moles and freckles and a higher risk of uveal melanoma, while also reassuring on the low infection rates following cataract surgery. The research found that people with atypical moles are 2.8 times more likely to develop uveal melanoma.
A study of nearly 157,000 people found that those with a family history of melanoma were nearly twice as likely to develop Parkinson's disease. Researchers suggest that the two diseases may share common genetic components.
Researchers discovered that atypical spitzoid tumors (ASTs) respond well to treatment, with 27 patients experiencing complete remission after a lymph node biopsy. The study suggests ASTs behave differently from other types of melanoma and may not be as aggressive.
Researchers examined the link between mobile phone use and uveal melanoma in a large study of 1,453 participants. No significant increased risk was found among regular users or those who used radio sets, suggesting that phone use may not be associated with this type of eye cancer.
A study published in The Lancet predicts John McCain's mortality rate due to melanoma, with a 10-year survival rate of 24%. The author suggests that McCain's risk improves if his cancer has not spread, reducing the annual mortality rate to 6% per year.
A genetic variant in the cyclin D1 gene is associated with a higher risk of developing melanoma. Individuals carrying two copies of the variant are 80% more likely to develop the disease. Extended and escalated dose chemotherapy shows no survival benefit in advanced melanoma cases.
A new study found a cancer gene in swordtail fish is conserved due to its role in attracting female mates. The melanoma gene creates an attractive natural marking that lures females, but the population also keeps the prevalence of the gene in check.
Researchers have developed a prototype test that can predict clinical outcome for melanoma patients, distinguishing between rapid and slow progression to Stage IV cancer. The test uses gene signature analysis and shows promise in identifying patient subtypes, which could improve treatment decisions and reduce clinical trial sizes.